Drug intelligence / Profile preview

RRG EXS

Development stage: Preclinical
Lead developer: Regenesys
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes
Administration: Topical, Intraarticular, Intramuscular, Subcutaneous

Overview

RRG EXS is an acellular regenerative biologic developed by Regenesys. It consists of a secretome containing exosomes and over 300 growth factors, designed to provide regenerative signaling for tissue repair. As an acellular therapy, it aims to deliver the therapeutic benefits of stem cell paracrine signaling without the risks associated with live cell transplantation, making it a candidate for various applications in regenerative medicine and tissue repair.

Brand names: RRG EXS
Other names: RRG EXS SecretomesAcellular secretome plus exosomesSecretome with 300+ growth factors

Beyond the preview

Go deeper on RRG EXS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RRG EXS.

Explore the full profile